{"name":"Védrines, Philippe, M.D.","slug":"v-drines-philippe-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Switch to a second anti-TNF drug alone","genericName":"Switch to a second anti-TNF drug alone","slug":"switch-to-a-second-anti-tnf-drug-alone","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"addition of azathioprine","genericName":"addition of azathioprine","slug":"addition-of-azathioprine","indication":"Rheumatoid arthritis","status":"marketed"}]}],"pipeline":[{"name":"Switch to a second anti-TNF drug alone","genericName":"Switch to a second anti-TNF drug alone","slug":"switch-to-a-second-anti-tnf-drug-alone","phase":"marketed","mechanism":"Switching to a second anti-TNF agent involves discontinuing one TNF inhibitor and initiating a different TNF inhibitor to maintain or restore therapeutic response in inflammatory conditions.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Inflammatory bowel disease (Crohn's disease, ulcerative colitis)","Psoriasis"],"catalyst":""},{"name":"addition of azathioprine","genericName":"addition of azathioprine","slug":"addition-of-azathioprine","phase":"marketed","mechanism":"Azathioprine is a purine analog that inhibits T-cell and B-cell proliferation by interfering with nucleotide synthesis, thereby suppressing immune responses.","indications":["Rheumatoid arthritis","Systemic lupus erythematosus","Inflammatory bowel disease (Crohn's disease and ulcerative colitis)","Autoimmune hepatitis","Organ transplant rejection prevention"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}